Jump to content

Andecaliximab

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Bender the Bot (talk | contribs) at 21:07, 4 October 2020 (→‎top: HTTP → HTTPS for World Health Organization, replaced: = http://www.who.int/ → =https://www.who.int/). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Andecaliximab
Monoclonal antibody
Type?
SourceChimeric (mouse/human)
Targetgelatinase B
Clinical data
Other namesGS-5745
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6396H9868N1680O2010S46
Molar mass143933.81 g·mol−1

Andecaliximab (INN;[1] development code GS-5745) is an experimental humanized monoclonal antibody designed for the treatment of cancer and inflammatory diseases.

This drug was developed by Gilead Sciences, Inc.[2]

Phase II and phase III trials for gastric cancer or gastroesophageal junction adenocarcinoma completed in 2019.

References

  1. ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Andecaliximab, American Medical Association.
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Andecaliximab&oldid=981862086"